[{"id":"0f9bc919-4e69-4675-bc62-35e94a94fa58","acronym":"INT22-09-01","url":"https://clinicaltrials.gov/study/NCT05521698","created_at":"2022-08-30T20:56:03.144Z","updated_at":"2025-02-25T13:41:12.118Z","phase":"Phase 1","brief_title":"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT05521698 - INT22-09-01","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/23/2025","start_date":" 04/23/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-21"},{"id":"d77f7e27-d759-4800-bb9d-f2404753c9ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222593","created_at":"2024-01-24T15:19:20.942Z","updated_at":"2025-02-25T14:10:34.092Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC","source_id_and_acronym":"NCT06222593","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AR • KLK2","pipe":" | ","alterations":" AR expression • KLK2 expression","tags":["AR • KLK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • KLK2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-17"},{"id":"fa762180-1ac0-4c2f-bfff-1035ccc3f515","acronym":"","url":"https://clinicaltrials.gov/study/NCT05669664","created_at":"2023-12-04T19:35:23.503Z","updated_at":"2025-02-25T15:20:12.831Z","phase":"Phase 2","brief_title":"Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers","source_id_and_acronym":"NCT05669664","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 04/11/2027","primary_completion_date":" 04/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2025-02-12"},{"id":"a8e4ef32-1344-482b-a5f5-187c3f5e9c87","acronym":"YATAGARASU","url":"https://clinicaltrials.gov/study/NCT04325828","created_at":"2021-01-18T20:57:18.226Z","updated_at":"2025-02-25T15:26:19.647Z","phase":"Phase 2","brief_title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT04325828 - YATAGARASU","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 06/09/2021","primary_completion_date":" 06/09/2021","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"e9087e98-84d9-4794-8123-a03a7c489eac","acronym":"CHAARTED2","url":"https://clinicaltrials.gov/study/NCT03419234","created_at":"2025-02-25T17:35:55.932Z","updated_at":"2025-02-25T17:35:55.932Z","phase":"Phase 2","brief_title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","source_id_and_acronym":"NCT03419234 - CHAARTED2","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 04/26/2018","start_date":" 04/26/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-29"},{"id":"ec583cea-b73e-4568-91d2-545510d640f1","acronym":"LEPRE","url":"https://clinicaltrials.gov/study/NCT05601700","created_at":"2025-02-25T18:07:59.797Z","updated_at":"2025-02-25T18:07:59.797Z","phase":"Phase 3","brief_title":"Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)","source_id_and_acronym":"NCT05601700 - LEPRE","lead_sponsor":"Ente Ospedaliero Ospedali Galliera","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 09/22/2022","start_date":" 09/22/2022","primary_txt":" Primary completion: 09/22/2029","primary_completion_date":" 09/22/2029","study_txt":" Completion: 09/22/2029","study_completion_date":" 09/22/2029","last_update_posted":"2025-01-27"},{"id":"ffa36ee9-c0da-420e-bc20-b503b2b0b217","acronym":"TBCRC 058","url":"https://clinicaltrials.gov/study/NCT06099769","created_at":"2023-10-25T19:14:04.278Z","updated_at":"2025-02-25T15:36:36.074Z","phase":"Phase 2","brief_title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT06099769 - TBCRC 058","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • AR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • AR positive","tags":["HER-2 • PD-L1 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)"],"overall_status":"Recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-20"},{"id":"8247cdb4-7bc6-434e-8424-d805cacb6db9","acronym":"LuCAB","url":"https://clinicaltrials.gov/study/NCT05340374","created_at":"2022-04-22T14:53:47.311Z","updated_at":"2025-02-25T17:37:46.899Z","phase":"Phase 1/2","brief_title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05340374 - LuCAB","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 06/20/2026","primary_completion_date":" 06/20/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-11-08"},{"id":"ff675977-05eb-4cd0-95e9-0479db1dd928","acronym":"CA209-8H3","url":"https://clinicaltrials.gov/study/NCT03650894","created_at":"2021-01-18T17:55:05.836Z","updated_at":"2025-02-25T14:27:31.343Z","phase":"Phase 2","brief_title":"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients","source_id_and_acronym":"NCT03650894 - CA209-8H3","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • bicalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-10-26"},{"id":"86b8bab9-8d79-4725-9a9e-c6c357e6b9b1","acronym":"CheckPRO","url":"https://clinicaltrials.gov/study/NCT05655715","created_at":"2022-12-19T14:58:39.293Z","updated_at":"2025-02-25T14:17:28.064Z","phase":"Phase 2","brief_title":"Checkpoint Inhibitors and SBRT for MCRPC","source_id_and_acronym":"NCT05655715 - CheckPRO","lead_sponsor":"Herlev and Gentofte Hospital","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 11/25/2019","start_date":" 11/25/2019","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-10-16"},{"id":"204a3645-717f-42ed-9810-3a60efcecc4a","acronym":"BTCRC-HN17-111","url":"https://clinicaltrials.gov/study/NCT03942653","created_at":"2021-01-18T19:24:28.517Z","updated_at":"2025-02-25T16:09:07.413Z","phase":"Phase 2","brief_title":"Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT03942653 - BTCRC-HN17-111","lead_sponsor":"Manish Patel","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-10-11"},{"id":"41b730ba-cb49-45dd-837c-967e8c4c2b8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03090165","created_at":"2021-01-18T15:13:36.654Z","updated_at":"2025-02-25T15:53:41.650Z","phase":"Phase 1/2","brief_title":"Ribociclib and Bicalutamide in AR+ TNBC","source_id_and_acronym":"NCT03090165","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • HER-2 negative + ER positive","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-10-11"},{"id":"9eb44888-36d6-498e-87f2-66cdcbe3ea1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02099864","created_at":"2021-01-17T17:57:53.255Z","updated_at":"2025-02-25T15:33:07.009Z","phase":"Phase 2","brief_title":"Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy","source_id_and_acronym":"NCT02099864","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • PTEN • AR • RB1","pipe":" | ","alterations":" PTEN mutation • AR splice variant 7","tags":["TP53 • PTEN • AR • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/05/2014","start_date":" 02/05/2014","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-09-19"},{"id":"db437829-c154-4ef1-a95d-32ea4e2d953d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02676986","created_at":"2021-01-18T13:03:06.360Z","updated_at":"2025-02-25T15:33:36.075Z","phase":"Phase 2","brief_title":"Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer","source_id_and_acronym":"NCT02676986","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" AR positive • AR expression","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive • AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 08/10/2015","start_date":" 08/10/2015","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2024-07-04"},{"id":"893db886-c712-4cce-b597-bb3b00601a44","acronym":"DISCOVARY","url":"https://clinicaltrials.gov/study/NCT05694819","created_at":"2023-01-23T14:59:43.274Z","updated_at":"2025-02-25T17:25:58.308Z","phase":"Phase 2","brief_title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","source_id_and_acronym":"NCT05694819 - DISCOVARY","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/17/2020","start_date":" 04/17/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-21"},{"id":"3d98dd1f-987f-4c68-94e3-38adc1f3cdfa","acronym":"BAT-RAD","url":"https://clinicaltrials.gov/study/NCT04704505","created_at":"2021-01-19T20:51:15.415Z","updated_at":"2025-02-25T17:24:58.474Z","phase":"Phase 2","brief_title":"Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04704505 - BAT-RAD","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-18"},{"id":"c39317e9-2ffe-4fe5-b487-781ec7511b8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923180","created_at":"2021-01-18T14:21:11.868Z","updated_at":"2024-07-02T16:34:25.763Z","phase":"Phase 2","brief_title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","source_id_and_acronym":"NCT02923180","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression","tags":["AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"},{"id":"20fd2a0a-62cd-4f70-ac61-940bf442c722","acronym":"","url":"https://clinicaltrials.gov/study/NCT06433804","created_at":"2024-06-01T04:16:19.723Z","updated_at":"2024-07-02T16:34:59.998Z","phase":"","brief_title":"Clinicopathological Parameters of HER2 Low Breast Cancers","source_id_and_acronym":"NCT06433804","lead_sponsor":"Vardhman Mahavir Medical College And Safdarjung Hospital","biomarkers":" HER-2 • PGR • AR","pipe":"","alterations":" ","tags":["HER-2 • PGR • AR"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-05-30"},{"id":"d79bfdb8-ad5a-46da-91a6-a2f9ca67b203","acronym":"DynaMO","url":"https://clinicaltrials.gov/study/NCT02703623","created_at":"2021-01-18T13:12:02.865Z","updated_at":"2024-07-02T16:35:03.313Z","phase":"Phase 2","brief_title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02703623 - DynaMO","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 05/18/2016","start_date":" 05/18/2016","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-16"},{"id":"924f441f-af1d-4089-89c9-8c65da31f6a6","acronym":"NCI-2021-12428","url":"https://clinicaltrials.gov/study/NCT05183828","created_at":"2022-01-11T17:56:17.517Z","updated_at":"2024-07-02T16:35:05.369Z","phase":"Phase 4","brief_title":"Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer","source_id_and_acronym":"NCT05183828 - NCI-2021-12428","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • AR • HSD3B1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • AR • HSD3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/23/2022","start_date":" 01/23/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"c675e0ca-7f1a-4e3c-8775-d10e0e747837","acronym":"","url":"https://clinicaltrials.gov/study/NCT03358563","created_at":"2024-05-03T20:26:05.283Z","updated_at":"2025-02-25T16:31:15.404Z","phase":"Phase 1","brief_title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","source_id_and_acronym":"NCT03358563","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" AR • EPCAM","pipe":"","alterations":" ","tags":["AR • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • bicalutamide • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 08/10/2021","primary_completion_date":" 08/10/2021","study_txt":" Completion: 09/02/2022","study_completion_date":" 09/02/2022","last_update_posted":"2024-05-03"},{"id":"14331834-8f2b-4486-822e-55a18617a637","acronym":"","url":"https://clinicaltrials.gov/study/NCT02007512","created_at":"2021-01-18T09:09:59.824Z","updated_at":"2024-07-02T16:35:07.270Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT02007512","lead_sponsor":"Pfizer","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" AR expression","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 09/23/2016","primary_completion_date":" 09/23/2016","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-26"},{"id":"acac02cd-c592-4eb3-b05a-a4f2485bc521","acronym":"DUCT","url":"https://clinicaltrials.gov/study/NCT05513365","created_at":"2022-08-24T21:07:35.191Z","updated_at":"2024-07-02T16:35:07.770Z","phase":"Phase 2","brief_title":"Phase II Dutasteride in Combination With CAB vs CAB in SDC","source_id_and_acronym":"NCT05513365 - DUCT","lead_sponsor":"Radboud University Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-04-24"},{"id":"a582d818-66bf-4d29-99ae-6395bae8c930","acronym":"","url":"https://clinicaltrials.gov/study/NCT03700099","created_at":"2021-01-18T18:08:05.718Z","updated_at":"2025-02-25T15:25:55.463Z","phase":"Phase 2","brief_title":"Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide","source_id_and_acronym":"NCT03700099","lead_sponsor":"Instituto do Cancer do Estado de São Paulo","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/03/2019","start_date":" 09/03/2019","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-15"}]